Selecta Biosciences, Inc.: Immune tolerance platform (ImmTOR) developed in combo with rare disease therapies. SEL-212 (chronic refractory gout) in COMPARE Ph 2 trial vs KRYSTEXXA®; topline data mid-2020. Gene tx pipeline in preclinical development with ImmTOR where re-dosing require. AskBio collab.
Based in...
US - New England
Clinical Stage
Phase l or ll
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Gene Therapy
480 Arsenal Way
Watertown, MA 02472
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Selecta Biosciences, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Vivo Capital LLC 17.52 7,846,509 21.34 13F 2020-03-31
Mangrove Partners 12.39 5,548,857 15.09 13F 2020-03-31
Ecor1 Capital LLC 10.27 4,597,701 12.51 13F 2020-03-31
BVF, Inc. 8.06 3,609,472 9.82 13F 2020-03-31
Artal Group SA 7.62 3,413,629 9.29 13F 2020-03-31
Boxer Capital LLC 7.33 3,284,072 8.93 13F 2020-03-31
Wasatch Advisors, Inc. 7.20 3,223,602 8.77 13F 2020-03-31
Polaris Venture Management Co. V LLC 6.19 2,773,479 7.54 13F 2020-03-31
OrbiMed Advisors LLC 5.79 2,593,869 7.06 13F 2020-03-31
Millennium Management LLC 5.75 2,575,045 7.00 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.